Abstract Body

Background

The induction of broadly neutralizing antibodies (bNAbs) remains a major challenge in the development of an effective preventive HIV vaccine. To target transmitted-founder (T/F) viruses, we designed a SOSIP protein based on an acutely infected individual who naturally developed bNAbs (“early neutralizer”) and evaluated this vaccine prototype in HIV-negative volunteers.

Methods

The HIVACFOUND study is a Phase 1 clinical trial assessing the safety and immunogenicity of the HIV-1 envelope-based vaccine 763SIP8/MPLA-5. Twelve healthy adults received four intramuscular immunizations with 100 μg of SOSIPv8.2-763 formulated with 500 μg of MPLA liposomes at weeks 0, 8, 24, and 48. The primary endpoint was safety and tolerability, and the secondary endpoint was induction of humoral immune responses, including bNAbs. Anti-HIV antibodies against T/F and chronic envelopes from clades A, B, and C were measured by BAMA. Neutralization was assessed using recombinant viruses carrying envelopes from clade B T/F (REJO4541.67, THRO4156.18), chronic clade A (VI191), and clade B (SF162, JR-FL, NL4.3).

Results

Safety. A total of 70 adverse events (AEs) were reported, most of which were local reactions (injection site pain and tenderness). The majority were mild (86.6%) or moderate (13.4%). Binding antibodies were detected at week 10, two weeks after the second immunization, showing strong reactivity with the autologous 763 SOSIP trimer and the group M consensus ConM trimer. Robust cross-reactivity was observed with most other clade B trimers, moderate with the clade A BG505 trimer, and weak with clade C trimers. Neutralizing activity emerged at week 48, prior to the fourth dose. Seven of twelve participants developed detectable neutralization titers (ID50: 1:30–1:200) against both autologous and heterologous clade B viruses (REJO4541.67, THRO4156.18, JR-FL, SF162, and NL4.3). Lack of an asparagine at position 197 increased neutralization sensitivity for the autologous virus and for JR-FL (D197) compared to JR-CSF (N197), but introducing the N197Q mutation did not affect REJO neutralization. 

Conclusions

Immunization with 763SIP8/MPLA-5, based on a T/F envelope, was safe, well tolerated, and induced both binding and neutralizing antibodies against the autologous immunogen and other clade B strains. Glycosylation at position 197 appears to contribute to the glycan shield and resistance to bNAbs in some strains.